Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Investigation of a new 1,3-diarylpropenone as a potential antimitotic agent targeting bladder carcinoma
Anti-Cancer Drugs, 07/02/09
Martel-Frachet V et al. - After treating the cells with IPP51 for 24 h, the title compound induced a predominant and reversible G2+M accumulation at the prometaphase stage of mitosis. However, when used for a longer period, it leads to cell apoptosis. These results suggest that the compound has potential anticancer activities, which could be useful in bladder cancer treatment.
Related Articles
High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression
BMC Cancer, 11/13/09
Relevance Score: 70%%
Evidence-based Principles of Bladder Cancer and Diet
Urology, 10/21/09
Relevance Score: 70%%
Incidence analyses of bladder cancer in the Nile delta region of Egypt
Cancer Epidemiology, 10/20/09
Relevance Score: 70%%
Biomarkers in bladder cancer
BJU International, 10/01/09
Relevance Score: 70%%
Diagnosis and Treatment of Bladder Cancer
American Family Physician, 10/01/09
Relevance Score: 70%%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis
Oncogene, 11/25/09
Extrapulmonary small cell carcinoma in breast and prostate
Clinical and Translational Oncology, 11/25/09
Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients
Cancer, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


